Sandoz Publishes Nine-Month 2026 Sales Update Presentation
Bitget2026/10/28 06:03- Sandoz reported a 40-asset biosimilar pipeline in its nine-month 2026 sales update.
- Biosimilar pertuzumab reached regulatory submission in the European Union.
- Pyzchiva held the leading biosimilar position across major European markets; global biosimilar penetration reached 54%.
- Hyrimoz continued gaining European market share, supported by strong volume momentum.
- Afqlir launched across 22 European markets, becoming a key contributor to regional growth.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
